IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology.
Flawless balance sheet with reasonable growth potential.
Share Price & News
How has IRIDEX's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IRIX's share price has been volatile over the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: IRIX underperformed the US Medical Equipment industry which returned 19.6% over the past year.
Return vs Market: IRIX underperformed the US Market which returned 17.9% over the past year.
Price Volatility Vs. Market
How volatile is IRIDEX's share price compared to the market and industry in the last 5 years?
Simply Wall St News
6 days ago | Simply Wall StIf You Had Bought IRIDEX (NASDAQ:IRIX) Stock Three Years Ago, You'd Be Sitting On A 78% Loss, Today
1 month ago | Simply Wall StWill IRIDEX (NASDAQ:IRIX) Spend Its Cash Wisely?
1 month ago | Simply Wall StIRIDEX Corporation's (NASDAQ:IRIX) Path To Profitability
Is IRIDEX undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IRIX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate IRIX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: IRIX is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: IRIX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IRIX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IRIX is good value based on its PB Ratio (1.9x) compared to the US Medical Equipment industry average (4.1x).
How is IRIDEX forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IRIX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: IRIX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: IRIX's is expected to become profitable in the next 3 years.
Revenue vs Market: IRIX's revenue (11% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: IRIX's revenue (11% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IRIX's Return on Equity is forecast to be high in 3 years time
How has IRIDEX performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IRIX is currently unprofitable.
Growing Profit Margin: IRIX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IRIX is unprofitable, and losses have increased over the past 5 years at a rate of -53.3% per year.
Accelerating Growth: Unable to compare IRIX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IRIX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.7%).
Return on Equity
High ROE: IRIX has a negative Return on Equity (-42.14%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is IRIDEX's financial position?
Financial Position Analysis
Short Term Liabilities: IRIX's short term assets ($31.2M) exceed its short term liabilities ($9.3M).
Long Term Liabilities: IRIX's short term assets ($31.2M) exceed its long term liabilities ($2.7M).
Debt to Equity History and Analysis
Debt Level: IRIX is debt free.
Reducing Debt: IRIX has not had any debt for past 5 years.
Inventory Level: IRIX has a high level of physical assets or inventory.
Debt Coverage by Assets: IRIX's debt is covered by short term assets (assets are 7.0296686583626E+16x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IRIX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: IRIX has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of -58.9% each year.
What is IRIDEX's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IRIX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate IRIX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IRIX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IRIX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IRIX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
David Bruce (60yo)
Mr. David I. Bruce has been President and Chief Executive Officer at IRIDEX Corporation since May 21, 2019. Mr Bruce has been a Director of IRIDEX Corporation since April 13, 2018. He served as the Chief E ...
|VP of Finance & Controller||1.2yrs||no data||0.26% $118.2k|
|Chief Operating Officer||0yrs||no data||0.16% $70.6k|
|Head of Investor Relations||0yrs||no data||no data|
|Vice President of Clinical Affairs||2.3yrs||US$602.50k||no data|
Experienced Management: IRIX's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
|Independent Director||0.8yrs||US$53.99k||0.036% $16.3k|
|Chairman||0.3yrs||no data||0.088% $39.4k|
|Independent Director||0.8yrs||no data||no data|
|Independent Director||1.3yrs||US$39.90k||0.26% $118.4k|
|Independent Director||1.8yrs||US$104.15k||0.041% $18.6k|
Experienced Board: IRIX's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.8%.
IRIDEX Corporation's company bio, employee growth, exchange listings and data sources
- Name: IRIDEX Corporation
- Ticker: IRIX
- Exchange: NasdaqGM
- Founded: 1989
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$44.929m
- Shares outstanding: 13.78m
- Website: https://www.iridex.com
Number of Employees
- IRIDEX Corporation
- 1212 Terra Bella Avenue
- Mountain View
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|IRIX||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Feb 1996|
|IX4||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Feb 1996|
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. The company offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. It also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. In addition, the company offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system that delivers laser to treat glaucoma; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. It serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, and office clinics. IRIDEX Corporation markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was founded in 1989 and is headquartered in Mountain View, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/23 00:42|
|End of Day Share Price||2020/02/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.